English (UK)
中文版Alex Li
TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.
TF Capital
Managing DirectorMr Wei Li
Jianmin Group (600976.SSE) is an integrated pharmaceutical company with a major focus on pediatric product development, manufacture, and marketing. Founded in 1953, headquartered in Wuhan, the largest city in Central China, its history can be traced back to 17th century. Jianmin has been a famous pharma brand in China among children and their parents for generations. Its rich pediatric portfolio ranges from nutrition, hematology, respiratory, digestive, CNS, to infections and common cold as well.
Jianmin Pharma Group
Head of Business DevelopmentAllen Li
Pregene is a world-leading cell and gene therapy company. Pregene is committed to develop innovative gene and cell therapy technologies and create reliable products from continued innovation and R&D. And pregene can provide CDMO service.
Shenzhen Pregene Biopharma Co., ltd
BD DirectorMs Sarai LI
Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.
and the largest allergen preparation supplier in Asia.
WolwoPharma
BDXuexin Li
Bionus Biotechnology was established in 2018， with an angel investment of a Finnish Company Currently we have 15 team members, 10 full-time, and 100% master's degree or above. Bionus has in-depth cooperation with the Karolinska Institute , Tokyo Medical and Dental University and Machine Learning Tokyo, the core members of the team had the background of Nobel Prize laureate in 2018, Mr. Tasuku Honjo.
The team currently covers 2 major layouts (AI-assisted small molecule chemical drug screening and creation of new peptide vaccines), 6 types of diseases, 12 pipelines, of which the fastest is a First in class:
At present, we are looking forward to the project financing of the anti-tumor CTLA-4 novel peptide vaccine of 10 million yuan. The main United Statesges is to complete the vaccine safety evaluation before the IND. The current anti-tumor CTLA-4 new peptide vaccine, preclinical trials have been nearly completed, and the effect is obvious. We are confident to make new technological innovations in tumor vaccines.
The team currently covers 2 major layouts (AI-assisted small molecule chemical drug screening and creation of new peptide vaccines), 6 types of diseases, 12 pipelines, of which the fastest is a First in class:
At present, we are looking forward to the project financing of the anti-tumor CTLA-4 novel peptide vaccine of 10 million yuan. The main United Statesges is to complete the vaccine safety evaluation before the IND. The current anti-tumor CTLA-4 new peptide vaccine, preclinical trials have been nearly completed, and the effect is obvious. We are confident to make new technological innovations in tumor vaccines.
Responsive Web Design powered by 